Regionally specific effects of acute and chronic nicotine on rates of catecholamine and 5-hydroxytryptamine synthesis in rat brain

European Journal of Pharmacology
S N MitchellJ A Gray

Abstract

Acute (-)-nicotine administration (0.4 and 0.8 mg/kg s.c.) produced a regionally specific increase in the rate of catecholamine synthesis in the rat nucleus accumbens, hypothalamus and hippocampus but not elsewhere, including the caudate-putamen. In all regions rates of 5-hydroxytryptamine synthesis were unaffected. (-)-Cotinine (0.4 and 0.8 mg/kg), the major metabolite of (-)-nicotine was without effect. (-)-Nicotine-induced increase in catecholamine synthesis occurred by a direct stimulation of central nicotinic receptors, as mecamylamine (5 mg/kg) but not hexamethonium (5 mg/kg) was an effective antagonist. Following repeated daily injections of (-)-nicotine (0.8 mg/kg) for up to 28 days, the induced catecholamine response following a subsequent challenge was unaffected in the nucleus accumbens and hypothalamus, but was increased in the hippocampus. This effect persisted for up to 14 days following withdrawal. Rates of 5-hydroxytryptamine synthesis remained unaltered after chronic pretreatment.

References

Jan 15, 1978·European Journal of Pharmacology·D NaquiraH Viveros
May 1, 1979·Pharmacology, Biochemistry, and Behavior·K FuxeT Hökfelt
Jan 1, 1978·Biochemical Pharmacology·L ArquerosE Zunino
Jan 1, 1977·Pharmacology, Biochemistry, and Behavior·P C Hatchell, A C Collins
Mar 1, 1975·Pharmacology, Biochemistry, and Behavior·D J BalfourA Longden
Nov 1, 1987·Journal of Neurochemistry·P P RowellA C Garner
Nov 1, 1986·Neurology·J A Baron
Dec 16, 1986·European Journal of Pharmacology·A ImperatoG Di Chiara
Jul 1, 1972·Biochemical Pharmacology·G H Hall, D M Turner
Jun 29, 1973·Psychopharmacologia·I P StolermanM E Jarvik
Feb 6, 1974·Psychopharmacologia·I P StolermanM E Jarvik
Sep 1, 1972·British Journal of Pharmacology·C F Morrison, J A Stephenson
Jan 1, 1982·Pharmacology & Therapeutics·D J Balfour
Feb 1, 1983·British Journal of Pharmacology·P B Clarke, R Kumar
Sep 1, 1980·Pharmacology, Biochemistry, and Behavior·T G HeffnerL S Seiden

❮ Previous
Next ❯

Citations

Apr 25, 1990·European Journal of Pharmacology·S N MitchellJ A Gray
Jun 1, 1995·Neuropharmacology·J L Galzi, J P Changeux
Apr 1, 1992·Pharmacology, Biochemistry, and Behavior·M D Schechter, S M Meehan
Jan 1, 1993·Brain Research. Brain Research Reviews·P W Kalivas
Oct 26, 2000·European Journal of Pharmacology·M R ZarrindastB Gharib
Dec 25, 2002·European Journal of Pharmacology·Paul FredricksonElliott Richelson
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Pallab SethSandra E File
Oct 12, 2002·Pharmacology, Biochemistry, and Behavior·T A GreenM T Bardo
May 20, 1998·Pharmacology, Biochemistry, and Behavior·D J BalfourM Al-Aloul
Jan 1, 1996·Pharmacology & Therapeutics·D J Balfour, K O Fagerström
Jun 28, 1992·Annals of the New York Academy of Sciences·J P TassinJ Glowinski
Aug 1, 1990·The Journal of Pharmacy and Pharmacology·Y K Fung
Oct 16, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·P VezinaW N Green
Apr 18, 2007·Journal of Neurochemistry·Jessika UrbanaviciusFederico Dajas
Sep 10, 1993·Brain Research·E B RibeiroR J Wurtman
Oct 1, 1990·Biochemical Pharmacology·P B Clarke
Sep 26, 2015·Pharmacological Reviews·Esa R KorpiGavin S Dawe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.